Vnitr Lek 2012, 58(3):221-227

Secondary dyslipidemias

V. Vargová1,*, M. Pytliak2, V. Mechírová2,3
1 III. interná klinika Lekárskej fakulty UPJŠ a UN L. Pasteura Košice, Slovenská republika, prednosta prof. MUDr. Daniel Pella, PhD.
2 Ústav ošetrovateľstva Lekárskej fakulty UPJŠ Košice, Slovenská republika, prednostka prof. MUDr. Viola Mechírová, CSc.
3 I. interná klinika Lekárskej fakulty UPJŠ a UN L. Pasteura Košice, Slovenská republika, prednostka prof. MUDr. Ivica Lazúrová, CSc.

Dyslipidemias rank among the most important preventabile factors of atherogenesis and its progression. This topic is increasingly being discussed as e.g. more than 50% of Slovak population die on atherosclerotic complications. According to etiology we distinguish primary dyslipidemias with strictly genetic background and secondary ones with origin in other disease or pathological state. Secondary dyslipidemias accompany various diseases, from common (endocrinopathies, renal diseases etc) to rare ones (thesaurismosis etc.) and represents one of symptoms of these diseases. Apart from particular clinical follow up of diagnosed dysipidemias, basic screening and secondary causes as well as treatment due to updated guidelines is recuired. In this review we present the most frequent dyslipidemias of clinical practice.

Keywords: secondary dyslipidemia; diabetes mellitus; nefrotic syndrome; cholestasis; alcohol

Received: September 24, 2009; Accepted: December 2, 2011; Published: March 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vargová V, Pytliak M, Mechírová V. Secondary dyslipidemias. Vnitr Lek. 2012;58(3):221-227.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126. Go to original source... Go to PubMed...
    2. Anitschkow N, Chalatow S. Über experimentelle cholesterinäse und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse. Zbl Allg Pathol Anat 1913; 24: 1.
    3. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 1986; 35: 530-545. Go to original source... Go to PubMed...
    4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497. Go to original source... Go to PubMed...
    5. Vráblik M, Češka R. Sekundární dyslipoproteinémie. Via pract 2004; 1: 14-17.
    6. Wilson PW, Kannel WB, Anderson KM. Lipids, glucose tolerance and vascular disease: the Framingham Study. Monogr Atheroscler 1985; 13: 1-11.
    7. Fábryová Ľ. Diabetická dyslipidémia - dôležitá súčasť komplexnej starostlivosti o diabetikov 2. typu. Via pract 2005; 2: 6-10.
    8. Štulc T, Češka R. Léčba dyslipidemie u metabolického syndromu. Vnitř Lék 2009; 55: 626-630. Go to PubMed...
    9. Tkáč I, Fábryová Ľ, Klimeš I et al. Manažment dyslipidémií u pacientov s diabetes mellitus. Vyjadrenie stanoviska Slovenskej diabetologickej spoločnosti. Interná Med 2004; 4: 311-317.
    10. Vaverková H, Soška V, Rosolová H et al. Czech Atherosclerosis Society. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181-197. Go to PubMed...
    11. Bláha V, Mistrík E. Hypolipidemika a diabetes mellitus. Vnitř Lék 2009; 55: 357-362. Go to PubMed...
    12. Češka R, Tesař V. Diabetes, dyslipidemie a onemocnění ledvin. Vnitř Lék 2008; 54: 511-517. Go to PubMed...
    13. Tkáč I. Stratégia prevencie rozvoja aterosklerózy pri diabete 2. typu. Kardiológia pre prax 2004; 3: 160-165.
    14. Palmajová R. Význam kombinovanej hypolipidemickej liečby pre pacientov s metabolickým syndrómom. Interní medicína pro praxi 2009; 11: 298-300.
    15. Babčák M, Merčiaková M, Kmec J et al. Diabetes mellitus 2. typ a artériová hypertenzia - najnovšie poznatky. Diabetes a obezita 2004; 4: 15-41.
    16. Chawla V, Greene T, Beck GJ et al. Hyperlipidemia and Long-Term Outcomes in Nondiabetic Chronic Kidney Disease. Clin J Am Soc Nephrol 2010; 5: 1582-1587. Go to original source... Go to PubMed...
    17. Chan CM. Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore 2005; 34: 31-35. Go to original source...
    18. Chamney M, Pugh-Clarke K, Kafkia T. Management of co-morbid diseases in a patient with established renal failure. J Ren Care 2009; 35: 151-158. Go to original source... Go to PubMed...
    19. Wanner C, Krane V, Metzger T et al. Lipid changes and statins in chronic renal insufficiency and dialysis. J Nephrol 2001; 14 Suppl 4: S76-S80. Go to PubMed...
    20. Sorokin A, Brown JL, Thompsona PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis 2007; 194: 293-299. Go to original source... Go to PubMed...
    21. Studeník P. Poruchy metabolismu lipidů u jaterních onemocnění. Vnitř Lek 2000; 46: 547-548. Go to PubMed...
    22. Duntas LH. Thyroid disease and lipids. Thyroid 2002; 12: 287-293. Go to original source... Go to PubMed...
    23. Jiskra J. Změny svalové tkáně u hypothyreózy. Vnitř Lék 2001; 47: 609-612. Go to PubMed...
    24. Graham I, Atar D, Borch-Johnsen K et al. European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375-2414. Go to original source... Go to PubMed...
    25. Weinbrenner T, Züger M, Jakoby GE et al. Lipoprotein metabolism in patients with anorexia nervosa: a case - control study investigating the mechanisms leading to hypercholesterolaemia. Br J Nutr 2004; 91: 959-969. Go to original source... Go to PubMed...
    26. Žák A, Vecka M, Tvrziská E et al. Composition of Plasma Fatty Acids and Non-Cholesterol Sterols in Anorexia Nervosa. Physiol Res 2005; 54: 443-451. Go to original source...
    27. Hannuksela ML, Liisanantt MK, Savolainen MJ. Effect of alcohol on lipids and lipoproteins in relation to atherosclerosis. Crit Rev Clin Lab Sci 2002; 39: 225-283. Go to original source... Go to PubMed...
    28. Pravdová E, Fisková M. Alcohol intake modulates hormonal activity of adipose tissue. Endocr Regul 2006; 40: 91-104. Go to PubMed...
    29. Oneta CM. Pathogenese und Management der alkoholischen Lebererkrankung: Teil 2: Diagnostik und Behandlung. Schweiz Med Forum 2004; 4: 131-137. Go to original source...
    30. Feinman L, Lieber CS. Ethanol and lipid metabolism. Editorial. Am J Clin Nutr 1999; 70: 791-792. Go to original source... Go to PubMed...
    31. Soška V. Sekundární dyslipidémie a jejich léčba. Vnitř Lék 2007; 53: 396-401. Go to PubMed...
    32. Imataka K. Alcohol or drug induced hyperlipidemia. Nippon Rinsho 1990; 48: 2599-2604.
    33. Soška V, Fiala J, Nebeská K et al. Sekundární dyslipidemie navozená současnými perorálními kontraceptivy. Vnitř Lék 2009; 55: 929-933. Go to PubMed...
    34. Saarelainen H, Laitinen T, Raitakari OT et al. Pregnancy-related hyperlipidemia and endothelial function in healthy women. Circ J 2006; 70: 768-772. Go to original source... Go to PubMed...
    35. Fábryová Ľ. Algoritmus diagnostiky a liečby dyslipoproteinémií. Interná medicína 2010; 10: 3-14.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.